Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report
BackgroundImmune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab are recommended as first-line therapies for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). However, their efficacy in neoadjuvant therapy remains uncertain.Case presentationWe report the case o...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1462993/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850243149522272256 |
|---|---|
| author | Ying Sun Guanghui Yang Ruijie Sun Fangli Cao |
| author_facet | Ying Sun Guanghui Yang Ruijie Sun Fangli Cao |
| author_sort | Ying Sun |
| collection | DOAJ |
| description | BackgroundImmune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab are recommended as first-line therapies for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). However, their efficacy in neoadjuvant therapy remains uncertain.Case presentationWe report the case of a 68-year-old male diagnosed with HNSCC who received neoadjuvant nivolumab (anti-PD-1 inhibitor) plus nab-paclitaxel and carboplatin. Biomarkerswere assessed by immunohistochemistry, and apoptosis-related molecules were analyzed via Western blotting. The patient achieved significant tumor regression and major pathological response (MPR) without severe adverse events. Post-treatment analyses revealed PD-L1 expression increased from 30% to 50% in tumor cells, CD8+ lymphocyte infiltration significantly improved, and Ki-67 expression was markedly reduced.ConclusionsThis case highlights the potential of combining ICIs with chemotherapy in neoadjuvant settings for HNSCC, providing mechanistic insights and clinical evidence for this emerging approach. Further studies are needed to establish the optimal neoadjuvant treatment regimen and identify patient populations most likely to benefit. |
| format | Article |
| id | doaj-art-ff5bd443450048f1832b7cf4575ff2df |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ff5bd443450048f1832b7cf4575ff2df2025-08-20T02:00:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.14629931462993Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case reportYing Sun0Guanghui Yang1Ruijie Sun2Fangli Cao3Department of Medical Oncology, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, ChinaDepartment of Medical Oncology, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, ChinaDepartment of Otolaryngology, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, ChinaDepartment of Medical Oncology, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, ChinaBackgroundImmune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab are recommended as first-line therapies for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). However, their efficacy in neoadjuvant therapy remains uncertain.Case presentationWe report the case of a 68-year-old male diagnosed with HNSCC who received neoadjuvant nivolumab (anti-PD-1 inhibitor) plus nab-paclitaxel and carboplatin. Biomarkerswere assessed by immunohistochemistry, and apoptosis-related molecules were analyzed via Western blotting. The patient achieved significant tumor regression and major pathological response (MPR) without severe adverse events. Post-treatment analyses revealed PD-L1 expression increased from 30% to 50% in tumor cells, CD8+ lymphocyte infiltration significantly improved, and Ki-67 expression was markedly reduced.ConclusionsThis case highlights the potential of combining ICIs with chemotherapy in neoadjuvant settings for HNSCC, providing mechanistic insights and clinical evidence for this emerging approach. Further studies are needed to establish the optimal neoadjuvant treatment regimen and identify patient populations most likely to benefit.https://www.frontiersin.org/articles/10.3389/fonc.2024.1462993/fullneoadjuvantimmunotherapychemotherapyhead and neck squamous cell carcinomamajor pathological response |
| spellingShingle | Ying Sun Guanghui Yang Ruijie Sun Fangli Cao Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report Frontiers in Oncology neoadjuvant immunotherapy chemotherapy head and neck squamous cell carcinoma major pathological response |
| title | Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report |
| title_full | Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report |
| title_fullStr | Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report |
| title_full_unstemmed | Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report |
| title_short | Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report |
| title_sort | neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus a case report |
| topic | neoadjuvant immunotherapy chemotherapy head and neck squamous cell carcinoma major pathological response |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1462993/full |
| work_keys_str_mv | AT yingsun neoadjuvantimmunotherapypluschemotherapyforsquamouscellcarcinomaoftheparanasalsinusacasereport AT guanghuiyang neoadjuvantimmunotherapypluschemotherapyforsquamouscellcarcinomaoftheparanasalsinusacasereport AT ruijiesun neoadjuvantimmunotherapypluschemotherapyforsquamouscellcarcinomaoftheparanasalsinusacasereport AT fanglicao neoadjuvantimmunotherapypluschemotherapyforsquamouscellcarcinomaoftheparanasalsinusacasereport |